Dihematoporphyrin derivative
PreclinicalSmall molecule
Dihematoporphyrin derivative is one of 9 small molecule programs targeting Corneal Neovascularization. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Corneal Neovascularization
#DrugCompanyPhaseTrials
1Avastin
BBio-Thera Solutions
Phase 3
Lucentis
RochePhase 1
Eylea
RegeneronPhase 1
Votrient
NovartisPhase 1
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Phase 1
GAMUNEX-C
Grifols Therapeutics LLCPhase 1
Il-1ra
UUniversity of Manchester
Phase 2
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Dihematoporphyrin derivative
MMedical College of Hampton Roads
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMedical College of Hampton Roads